Associate Professor Veysel Kayser

A15 - Pharmacy And Bank Building
The University of Sydney

Telephone +61 2 9351 3391

Website Contact Details

Biographical details

Veysel Kayser is an Associate Professor in the School of Pharmacy at the University of Sydney. He received his Ph.D. from the University of Leeds (UK) then performed post-doctoral research at the Max-Planck Institute (Germany) and at MIT (US). Before joining the University of Sydney he was a senior scientist at MIT.

He also consults for pharma and biotech companies and law firms.

Research interests

Associate Professor Kayser’s research focuses on the development of vaccines and biologics.

Specific areas of interest include:

  • Development of vaccines and biopharmaceuticals
    • Biosimilars and next-generation biologics (biobetters)
    • Therapeutic monoclonal antibodies (mAbs)
    • Rabies, influenza, Ebola, Crimean-Congo haemorrhagic virus, MERS
    • Protein folding and aggregation
    • Stabilization and formulation of biotherapeutics and vaccines
    • Molecular engineering of biopharmaceutical products
  • Development of novel methods to study biological products and vaccines
  • Nucleation and crystallization
  • Time-resolved fluorescence spectroscopy
  • Biophysical methods

Teaching and supervision

We are looking for researchers at all levels, please contact Associate Professor Kayser - (veysel.kayser@sydney.edu.au)

Current research students

Project title Research student
Development of Gold NPs-Antigen-Adjuvant based Novel Freeze-Foam Drying. Lung Cancer Vaccine to Maximize the Target Efficacy and Stability. Anisuzzman ANISUZZMAN
Development of antibody-targeted nanoparticles for cancer therapy Esteban CRUZ GONZALEZ
Anti-cancer properties of various plant extracts Candice MCKERTISH

Current projects

  • Monoclonal antibodies including biosimilars and biobetters
  • Vaccines
  • Nucleation and crystallisation

Associations

Multidisciplinary Advisory Board Member of Marie Bashir Institute

Member of Cancer Research Network

In the media

  • Explainer: what are biologics and biosimilars?by Veysel Kayser and Iqbal Ramzan

https://theconversation.com/explainer-what-are-biologics-and-biosimilars-45308

  • Biosimilars: Raising an "a" flag on biosimilars

Interview by Megan Haggan from The Australian Journal of Pharmacy

AJP, Volume 96 Issue 1144 (Oct 2015)

http://search.informit.org/documentSummary;res=IELHEA;dn=601271479946587

  • Why biologics are a big deal for the TPP

Interview by Peter Trute from Australian Associated Press, 6 October 2015

http://www.9news.com.au/national/2015/10/06/17/19/why-biologics-are-a-big-deal-for-the-tpp

  • Cranking it Up: Biotherapeutic Cell-Line Expression

Interview by Mark May from Biocompare, 21 February 2017

http://www.biocompare.com/Editorial-Articles/333939-Cranking-it-Up-Biotherapeutic-Cell-Line-Expression/

  • Biosimilars: Not just a generic

Interview by Megan Haggan from AJP, 11 May 2018

https://ajp.com.au/features/biosimilars-not-just-a-generic/

Keywords

Protein aggregation; Biotherapeutics; Monoclonal antibodies; Biosimilars, mAb, next-generation biologics, biobetters

Selected grants

2017

  • UNcle All-in-One Biologics Stability Platform with Robotic High Throughput Screening System for the Open Access, Multi-Disciplinary Bosch Molecular Biology Facility; Richardson D, Scolyer R, Murray M, Long G, Lay P, Mason R, Payne R, Kayser V, Kovacevic Z, Lee C; Cancer Institute NSW/Equipment Grant.
  • Ultra-high-performance microbalance, XPR2; Varamini P, Duong H, Grewal T, Kayser V, Gelissen I, Chrzanowski W, Boddy A; University of Sydney, Faculty of Pharmacy/Equipment Grant.

2016

  • Triggered delivery of an anticancer drug using a molecular handcuff; Wheate N, Marsh D, Kayser V; DVC Education/Small Educational Innovation Grant.

2013

  • Developing a Biotherapeutic Protein Delivery System for Pulmonary Tract; Kayser V, Chan H; University of Sydney, Faculty of Pharmacy/Equipment Grant.

2012

  • Development of Screening Tools for Influenza Vaccine Preparations for Their Stability and Aggregation Propensity; Kayser V; Sanofi Pasteur/Industrial Grant.

2010

  • Characterization and stabilization of Influenza Virus Vaccines; Kayser V; Sanofi Pasteur/Industrial Grant.

2008

  • Rational Design of Rabies Vaccine Formulation for Enhanced Stability; Kayser V; Sanofi Pasteur/Industrial Grant.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Kayser, V., Reslan, M. (2019). The effect of deuterium oxide on the conformational stability and aggregation of bovine serum albumin (forthcoming). Pharmaceutical Development and Technology, 23(10), 1030-1036. [More Information]
  • Reslan, M., Ranganathan, V., MacFarlane, D., Kayser, V. (2018). Choline ionic liquid enhances the stability of Herceptin� (trastuzumab). Chemical Communications, 54(75), 10622-10625. [More Information]
  • Dereli, A., Kayser, V. (2018). Crimean-Congo Hemorrhagic Fever: A bibliometric assessment of the literature. Journal of Infection and Public Health, 11(1), 147-148. [More Information]
  • Moussa, Y., Ong, Y., Perry, J., Cheng, Z., Kayser, V., Cruz, E., Kim, R., Sciortino, N., Wheate, N. (2018). Demonstration of in vitro host-guest complex formation and safety of para-sulfonatocalix[8]arene as a delivery vehicle for two antibiotic drugs. Journal of Pharmaceutical Sciences, 107(12), 3105-3111. [More Information]
  • Reslan, M., Kayser, V. (2018). Ionic liquids as biocompatible stabilizers of proteins. Biophysical Reviews, 10(3), 781-793. [More Information]
  • Cruz, E., Cain, J., Crossett, B., Kayser, V. (2018). Site-specific Glycosylation Profile of Influenza A (H1N1) Hemagglutinin Through Tandem Mass Spectrometry. Human Vaccines and Immunotherapeutics, 14(3), 508-517. [More Information]
  • Kuyucak, S., Kayser, V. (2017). Biobetters From an Integrated Computational/Experimental Approach. Computational and Structural Biotechnology Journal, 15, 138-145. [More Information]
  • Akkoc, S., Ilhan, I., Gok, Y., Kayser, V. (2017). Carbon-carbon bond formation catalyzed by PEPPSI Pd-NHC. Inorganica Chimica Acta, 461, 52-56. [More Information]
  • Elgundi, Z., Sifniotis, V., Reslan, M., Cruz, E., Kayser, V. (2017). Laboratory Scale Production and Purification of a Therapeutic Antibody. Journal of Visualized Experiments, 2017 (119), 1-8. [More Information]
  • Reslan, M., Demir, Y., Trout, B., Chan, H., Kayser, V. (2017). Lack of a synergistic effect of arginine�glutamic acid on the physical stability of spray-dried bovine serum albumin. Pharmaceutical Development and Technology, 22(6), 785-791. [More Information]
  • Akkoc, S., Kayser, V., Ilhan, I., Hibbs, D., Gok, Y., Williams, P., Hawkins, B., Lai, F. (2017). New compounds based on a benzimidazole nucleus: synthesis, characterization and cytotoxic activity against breast and colon cancer cell lines. Journal of Organometallic Chemistry, 839, 98-107. [More Information]
  • Sahin, Z., Akkoc, S., Neeleman, R., Haines, J., Kayser, V. (2017). Nile red fluorescence spectrum decomposition enables rapid screening of large protein aggregates in complex biopharmaceutical formulations like influenza vaccines. Vaccine, 35(23), 3026-3032. [More Information]
  • Sahin, Z., Akkoc, S., Kayser, V., Ilhan, I. (2017). Palladium N-Heterocyclic Carbene Complexes: Synthesis from Benzimidazolium Salts and Catalytic Activity in Carbon-carbon Bond-forming Reactions. Journal of Visualized Experiments, 125, 1-10. [More Information]
  • Demir, Y., Metin, A., Satiroglu, B., Solmaz, M., Kayser, V., Mader, K. (2017). Poly (methyl vinyl ether-co-maleic acid) � Pectin Based Hydrogel-Forming Systems: Gel, Film, and Microneedles. European Journal of Pharmaceutics and Biopharmaceutics, 117, 182-194. [More Information]
  • Kayser, V., Francon, A., Pinton, H., Saluzzo, J., Trout, B. (2017). Rational design of rabies vaccine formulation for enhanced stability. Turkish Journal of Medical Sciences, 47(3), 987-995. [More Information]
  • Elgundi, Z., Reslan, M., Cruz, E., Sifniotis, V., Kayser, V. (2017). The state-of-play and future of antibody therapeutics. Advanced Drug Delivery Reviews, 122, 2-19. [More Information]
  • Sari, Y., Akkoc, S., Gok, Y., Sifniotis, V., Ozdemir, I., Gunal, S., Kayser, V. (2016). Benzimidazolium-based novel silver N-heterocyclic carbene complexes: synthesis, characterisation and in vitro antimicrobial activity. Journal of Enzyme Inhibition and Medicinal Chemistry, 31(6), 1527-1530. [More Information]
  • Sahin, Z., Demir, Y., Kayser, V. (2016). Global kinetic analysis of seeded BSA aggregation. European Journal of Pharmaceutical Sciences, 86, 115-124. [More Information]
  • Wheate, N., Dickson, K., Kim, R., Nematollahi, A., Macquart, R., Kayser, V., Yu, G., Church, W., Marsh, D. (2016). Host-Guest Complexes of Carboxylated Pillar[n]arenes With Drugs. Journal of Pharmaceutical Sciences, 105(12), 3615-3625. [More Information]
  • Akkoc, S., Gok, Y., Ihan, I., Kayser, V. (2016). In situ generation of efficient palladium N-heterocyclic carbene catalysts using benzimidazolium salts for the Suzuki-Miyaura cross-coupling reaction. Current Organic Synthesis, 13(5), 761-766. [More Information]
  • Ilhan, I., Akkoc, S., Gok, Y., Upadhyay, P., Kayser, V. (2016). In vitro cytotoxic activities of new silver and PEPPSI palladium N-heterocyclic carbene complexes derived from benzimidazolium salts. Inorganica Chimica Acta, 449, 75-81. [More Information]
  • Akkoc, S., Gok, Y., Ilhan, I., Kayser, V. (2016). N-Methylphthalimide-substituted Benzimidazolium salts and PEPPSI Pd-NHC complexes: Synthesis, characterization and catalytic activity in carbon-carbon bond-forming reactions. Beilstein Journal of Organic Chemistry, 12, 81-88. [More Information]
  • Lee, K., Sahin, Z., Neeleman, R., Trout, B., Kayser, V. (2016). Quantitative determination of the surfactant-induced split ratio of influenza virus by fluorescence spectroscopy. Human Vaccines and Immunotherapeutics, 12(7), 1757-1765. [More Information]
  • Kayser, V., Chennamsetty, N., Voynov, V., Helk, B., Forrer, K., Trout, B. (2012). A screening tool for therapeutic monoclonal antibodies: Identifying the most stable protein and its best formulation based on thioflavin T binding. Biotechnology Journal, 7(1), 127-132. [More Information]
  • Kayser, V., Chennamsetty, N., Voynov, V., Helk, B., Trout, B. (2011). Conformational stability and aggregation of therapeutic monoclonal antibodies studied with ANS and Thioflavin T binding. mAbs, 3(4), 408-411. [More Information]
  • Kayser, V., Chennamsetty, N., Voynov, V., Helk, B., Forrer, K., Trout, B. (2011). Evaluation of a Non-Arrhenius Model for Therapeutic Monoclonal Antibody Aggregation. Journal of Pharmaceutical Sciences, 100(7), 2526-2542. [More Information]
  • Kayser, V., Chennamsetty, N., Voynov, V., Forrer, K., Helk, B., Trout, B. (2011). Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies. Biotechnology Journal, 6(1), 38-44. [More Information]
  • Chennamsetty, N., Voynov, V., Kayser, V., Helk, B., Trout, B. (2011). Prediction of protein binding regions. Proteins: Structure, Function, and Bioinformatics, 79(3), 888-897. [More Information]
  • Kayser, V., Chennamsetty, N., Voynov, V., Helk, B., Trout, B. (2011). Tryptophan-Tryptophan Energy Transfer and Classification of Tryptophan Residues in Proteins Using a Therapeutic Monoclonal Antibody as a Model. Journal of Fluorescence, 21(1), 275-288. [More Information]
  • Voynov, V., Chennamsetty, N., Kayser, V., Wallny, H., Helk, B., Trout, B. (2010). Design and Application of Antibody Cysteine Variants. Bioconjugate Chemistry, 21(2), 385-392. [More Information]
  • Chennamsetty, N., Voynov, V., Kayser, V., Helk, B., Trout, B. (2010). Prediction of Aggregation Prone Regions of Therapeutic Proteins. Russian Journal of Physical Chemistry B, 114(9), 6614-6624. [More Information]
  • Chennamsetty, N., Helk, B., Voynov, V., Kayser, V., Trout, B. (2009). Aggregation-Prone Motifs in Human Immunoglobulin G. Journal of Molecular Biology, 391(2), 404-413. [More Information]
  • Chennamsetty, N., Voynov, V., Kayser, V., Helk, B., Trout, B. (2009). Design of therapeutic proteins with enhanced stability. Proceedings of the National Academy of Sciences of the United States of America, 106(29), 11937-11942. [More Information]
  • Voynov, V., Chennamsetty, N., Kayser, V., Helk, B., Forrer, K., Zhang, H., Fritsch, C., Heine, H., Trout, B. (2009). Dynamic Fluctuations of Protein-Carbohydrate Interactions Promote Protein Aggregation. PloS One, 4(12), 1-10. [More Information]
  • Voynov, V., Chennamsetty, N., Kayser, V., Helk, B., Trout, B. (2009). Predictive tools for stabilization of therapeutic proteins. mAbs, 1(6), 580-582. [More Information]
  • Bartlett, S., Beddard, G., Jackson, R., Kayser, V., Kilner, C., Leach, A., Nelson, A., Oledzki, P., Parker, P., Reid, G., et al (2005). Comparison of the ATP binding sites of protein kinases using conformationally diverse bisindolylmaleimides. Journal of the American Chemical Society, 127(33), 11699-11708. [More Information]
  • Kayser, V., Turton, D., Aggeli, A., Beevers, A., Reid, G., Beddard, G. (2004). Energy migration in novel pH-Triggered self-assembled beta-sheet ribbons. Journal of the American Chemical Society, 126(1), 336-343. [More Information]
  • Reid, G., Whittaker, D., Day, M., Turton, D., Kayser, V., Kelly, J., Beddard, G. (2002). Femtosecond electron-transfer reactions in mono- and polynucleotides and in DNA. Journal of the American Chemical Society, 124(19), 55118-5527. [More Information]

Conferences

  • Kayser, V. (2019). The State-of-play and Future of Biosimilar and Biobetter mAbs. Applied Science Private University.
  • Kayser, V. (2017). Development of Novel Sensitive Methods for Biologics and Vaccine Formulations (Invited Speaker). The School of Chemistry & Molecular Biosciences University of Queensland.
  • Kayser, V. (2017). Novel analytical methods for the development of biologic and vaccine formulations (Invited Speaker). International Conference on Pharmacology & Regulatory Affairs.
  • Kayser, V. (2017). The Science Behind Developing Biosimilar Medications (Invited Speaker). Australian Pharmaceutical Physicians Association (APPA) QGM/AGM Biosimilar Symposium.
  • Kayser, V. (2017). The State-of-Play and Future of Antibody Therapeutics for Cancer (2017) Oncology Insights Meeting (Invited Speaker). Oncology Insights Meeting, Baxter Australia.
  • Kayser, V. (2017). The State-of-play and Future of Biosimilar and Biobetter mAbs (Plenary Speaker). Applied Science Private University Annual Conference.
  • Reslan, M., Kayser, V. (2016). Development of a Trastuzumab (Herceptin) Biobetter with Enhanced Stability and Binding Affinity to HER2. 2016 Sydney Cancer Conference (SCC2016), Sydney, Australia.
  • Kayser, V. (2016). Rational Approaches for Stabilisation and Development of Biosimilars and Biobetters (Invited speaker). Pfizer Global Supply.
  • Kayser, V. (2016). Vaccine Development Strategies and International State-of-Play. Vaccine Workshop.
  • Kayser, V. (2015). A Novel Quantitative Fluorescence Spectroscopy Method to Estimate the Surfactant- Induced Split Ratio of Influenza Virus. 5th Asia Pacific Global Summit and Expo on Vaccines and Vaccination.
  • Kayser, V. (2014). Mechanistic Insights into Flu Vaccine Degradation with Orthogonal Experimental Methods (Invited speaker). National Centre for Immunisation Research & Surveillance.
  • Kayser, V. (2014). Mechanistic Insights into mAB Aggregation and the Development of Novel Predictive Tools to Stabilize Therapeutic Proteins. 5th FIP Pharmaceutical Sciences World Congress (FIP PSWC 2014), Melbourne: International Pharmaceutical Federation.
  • Kayser, V. (2012). A Screening Tool for Therapeutic Monoclonal Antibodies: Identifying the Most Stable Protein and Its Best Formulation Based on Thioflavin T Binding. The Eight Annual Essential Protein Engineering Summit (PEGS 2012), Needham: Cambridge Healthtech Institute.
  • Kayser, V. (2012). Mechanistic Insights into Protein Aggregation and the Development of Rational Approaches and Predictive Tools to Stabilization of Biopharmaceuticals. International Conference and Exhibition on Biowaivers and Biosimilars.
  • Kayser, V. (2010). Degradation of Biological Drugs: Understanding and Modeling of Therapeutic mAb Aggregation & Improved Formulations of Vaccines. Bio-manufacturing (BioMAN).
  • Kayser, V. (2010). Understanding and Modeling of Therapeutic Monoclonal Antibody Aggregation. American Chemical Society Annual Meeting.
  • Kayser, V. (2009). Characterization of Rabies Virus Vaccine Inactivation. American Institute of Chemical Engineers Annual Meeting.
  • Kayser, V. (2009). Elucidating & Predicting Therapeutic Monoclonal Antibody Aggregation. Novartis Institutes for Biomedical Research.
  • Kayser, V. (2009). Stability and Aggregation of Therapeutic Monoclonal Antibodies: Determination of Aggregation Kinetic Rates with Accelerated Studies. American Institute of Chemical Engineers Annual Meeting.
  • Kayser, V. (2008). Elucidating Therapeutic Monoclonal Antibody Aggregation. American Institute of Chemical Engineers AnnualMeeting.
  • Kayser, V. (2003). Fast Dynamics in Engineered Self-Assembling Peptide Systems. ANUMOCP 13th Annual Symposium.
  • Kayser, V. (2003). Fluorescence Properties of Engineered Novel Self-Assembling Peptide Systems. NESBiC Annual Symposium.
  • Kayser, V. (2003). Ultrafast Spectroscopy of Designed Novel Self-Assembling Peptides. 3rd Year Talk.

Patents

  • Chennamsetty, N., Helk, B., Kayser, V., Trout, B., Voynov, V. (2010). Methods for identification of sites for IgG conjugation. Patent No. WO 2010141902 A2 20101209.
  • Chennamsetty, N., Helk, B., Kayser, V., Trout, B., Voynov, V. (2009). Immunoglobulins with reduced aggregation. Patent No. WO 2009155513 A2 20091223.
  • Chennamsetty, N., Helk, B., Trout, B., Kayser, V., Voynov, V. (2009). Methods to identify macromolecule binding and aggregation prone regions in proteins and uses therefore. Patent No. WO 2009155518 A1 20091223.

2019

  • Kayser, V., Reslan, M. (2019). The effect of deuterium oxide on the conformational stability and aggregation of bovine serum albumin (forthcoming). Pharmaceutical Development and Technology, 23(10), 1030-1036. [More Information]
  • Kayser, V. (2019). The State-of-play and Future of Biosimilar and Biobetter mAbs. Applied Science Private University.

2018

  • Reslan, M., Ranganathan, V., MacFarlane, D., Kayser, V. (2018). Choline ionic liquid enhances the stability of Herceptin� (trastuzumab). Chemical Communications, 54(75), 10622-10625. [More Information]
  • Dereli, A., Kayser, V. (2018). Crimean-Congo Hemorrhagic Fever: A bibliometric assessment of the literature. Journal of Infection and Public Health, 11(1), 147-148. [More Information]
  • Moussa, Y., Ong, Y., Perry, J., Cheng, Z., Kayser, V., Cruz, E., Kim, R., Sciortino, N., Wheate, N. (2018). Demonstration of in vitro host-guest complex formation and safety of para-sulfonatocalix[8]arene as a delivery vehicle for two antibiotic drugs. Journal of Pharmaceutical Sciences, 107(12), 3105-3111. [More Information]
  • Reslan, M., Kayser, V. (2018). Ionic liquids as biocompatible stabilizers of proteins. Biophysical Reviews, 10(3), 781-793. [More Information]
  • Cruz, E., Cain, J., Crossett, B., Kayser, V. (2018). Site-specific Glycosylation Profile of Influenza A (H1N1) Hemagglutinin Through Tandem Mass Spectrometry. Human Vaccines and Immunotherapeutics, 14(3), 508-517. [More Information]

2017

  • Kuyucak, S., Kayser, V. (2017). Biobetters From an Integrated Computational/Experimental Approach. Computational and Structural Biotechnology Journal, 15, 138-145. [More Information]
  • Akkoc, S., Ilhan, I., Gok, Y., Kayser, V. (2017). Carbon-carbon bond formation catalyzed by PEPPSI Pd-NHC. Inorganica Chimica Acta, 461, 52-56. [More Information]
  • Kayser, V. (2017). Development of Novel Sensitive Methods for Biologics and Vaccine Formulations (Invited Speaker). The School of Chemistry & Molecular Biosciences University of Queensland.
  • Elgundi, Z., Sifniotis, V., Reslan, M., Cruz, E., Kayser, V. (2017). Laboratory Scale Production and Purification of a Therapeutic Antibody. Journal of Visualized Experiments, 2017 (119), 1-8. [More Information]
  • Reslan, M., Demir, Y., Trout, B., Chan, H., Kayser, V. (2017). Lack of a synergistic effect of arginine�glutamic acid on the physical stability of spray-dried bovine serum albumin. Pharmaceutical Development and Technology, 22(6), 785-791. [More Information]
  • Akkoc, S., Kayser, V., Ilhan, I., Hibbs, D., Gok, Y., Williams, P., Hawkins, B., Lai, F. (2017). New compounds based on a benzimidazole nucleus: synthesis, characterization and cytotoxic activity against breast and colon cancer cell lines. Journal of Organometallic Chemistry, 839, 98-107. [More Information]
  • Sahin, Z., Akkoc, S., Neeleman, R., Haines, J., Kayser, V. (2017). Nile red fluorescence spectrum decomposition enables rapid screening of large protein aggregates in complex biopharmaceutical formulations like influenza vaccines. Vaccine, 35(23), 3026-3032. [More Information]
  • Kayser, V. (2017). Novel analytical methods for the development of biologic and vaccine formulations (Invited Speaker). International Conference on Pharmacology & Regulatory Affairs.
  • Sahin, Z., Akkoc, S., Kayser, V., Ilhan, I. (2017). Palladium N-Heterocyclic Carbene Complexes: Synthesis from Benzimidazolium Salts and Catalytic Activity in Carbon-carbon Bond-forming Reactions. Journal of Visualized Experiments, 125, 1-10. [More Information]
  • Demir, Y., Metin, A., Satiroglu, B., Solmaz, M., Kayser, V., Mader, K. (2017). Poly (methyl vinyl ether-co-maleic acid) � Pectin Based Hydrogel-Forming Systems: Gel, Film, and Microneedles. European Journal of Pharmaceutics and Biopharmaceutics, 117, 182-194. [More Information]
  • Kayser, V., Francon, A., Pinton, H., Saluzzo, J., Trout, B. (2017). Rational design of rabies vaccine formulation for enhanced stability. Turkish Journal of Medical Sciences, 47(3), 987-995. [More Information]
  • Kayser, V. (2017). The Science Behind Developing Biosimilar Medications (Invited Speaker). Australian Pharmaceutical Physicians Association (APPA) QGM/AGM Biosimilar Symposium.
  • Elgundi, Z., Reslan, M., Cruz, E., Sifniotis, V., Kayser, V. (2017). The state-of-play and future of antibody therapeutics. Advanced Drug Delivery Reviews, 122, 2-19. [More Information]
  • Kayser, V. (2017). The State-of-Play and Future of Antibody Therapeutics for Cancer (2017) Oncology Insights Meeting (Invited Speaker). Oncology Insights Meeting, Baxter Australia.
  • Kayser, V. (2017). The State-of-play and Future of Biosimilar and Biobetter mAbs (Plenary Speaker). Applied Science Private University Annual Conference.

2016

  • Sari, Y., Akkoc, S., Gok, Y., Sifniotis, V., Ozdemir, I., Gunal, S., Kayser, V. (2016). Benzimidazolium-based novel silver N-heterocyclic carbene complexes: synthesis, characterisation and in vitro antimicrobial activity. Journal of Enzyme Inhibition and Medicinal Chemistry, 31(6), 1527-1530. [More Information]
  • Reslan, M., Kayser, V. (2016). Development of a Trastuzumab (Herceptin) Biobetter with Enhanced Stability and Binding Affinity to HER2. 2016 Sydney Cancer Conference (SCC2016), Sydney, Australia.
  • Sahin, Z., Demir, Y., Kayser, V. (2016). Global kinetic analysis of seeded BSA aggregation. European Journal of Pharmaceutical Sciences, 86, 115-124. [More Information]
  • Wheate, N., Dickson, K., Kim, R., Nematollahi, A., Macquart, R., Kayser, V., Yu, G., Church, W., Marsh, D. (2016). Host-Guest Complexes of Carboxylated Pillar[n]arenes With Drugs. Journal of Pharmaceutical Sciences, 105(12), 3615-3625. [More Information]
  • Akkoc, S., Gok, Y., Ihan, I., Kayser, V. (2016). In situ generation of efficient palladium N-heterocyclic carbene catalysts using benzimidazolium salts for the Suzuki-Miyaura cross-coupling reaction. Current Organic Synthesis, 13(5), 761-766. [More Information]
  • Ilhan, I., Akkoc, S., Gok, Y., Upadhyay, P., Kayser, V. (2016). In vitro cytotoxic activities of new silver and PEPPSI palladium N-heterocyclic carbene complexes derived from benzimidazolium salts. Inorganica Chimica Acta, 449, 75-81. [More Information]
  • Akkoc, S., Gok, Y., Ilhan, I., Kayser, V. (2016). N-Methylphthalimide-substituted Benzimidazolium salts and PEPPSI Pd-NHC complexes: Synthesis, characterization and catalytic activity in carbon-carbon bond-forming reactions. Beilstein Journal of Organic Chemistry, 12, 81-88. [More Information]
  • Lee, K., Sahin, Z., Neeleman, R., Trout, B., Kayser, V. (2016). Quantitative determination of the surfactant-induced split ratio of influenza virus by fluorescence spectroscopy. Human Vaccines and Immunotherapeutics, 12(7), 1757-1765. [More Information]
  • Kayser, V. (2016). Rational Approaches for Stabilisation and Development of Biosimilars and Biobetters (Invited speaker). Pfizer Global Supply.
  • Kayser, V. (2016). Vaccine Development Strategies and International State-of-Play. Vaccine Workshop.

2015

  • Kayser, V. (2015). A Novel Quantitative Fluorescence Spectroscopy Method to Estimate the Surfactant- Induced Split Ratio of Influenza Virus. 5th Asia Pacific Global Summit and Expo on Vaccines and Vaccination.

2014

  • Kayser, V. (2014). Mechanistic Insights into Flu Vaccine Degradation with Orthogonal Experimental Methods (Invited speaker). National Centre for Immunisation Research & Surveillance.
  • Kayser, V. (2014). Mechanistic Insights into mAB Aggregation and the Development of Novel Predictive Tools to Stabilize Therapeutic Proteins. 5th FIP Pharmaceutical Sciences World Congress (FIP PSWC 2014), Melbourne: International Pharmaceutical Federation.

2012

  • Kayser, V., Chennamsetty, N., Voynov, V., Helk, B., Forrer, K., Trout, B. (2012). A screening tool for therapeutic monoclonal antibodies: Identifying the most stable protein and its best formulation based on thioflavin T binding. Biotechnology Journal, 7(1), 127-132. [More Information]
  • Kayser, V. (2012). A Screening Tool for Therapeutic Monoclonal Antibodies: Identifying the Most Stable Protein and Its Best Formulation Based on Thioflavin T Binding. The Eight Annual Essential Protein Engineering Summit (PEGS 2012), Needham: Cambridge Healthtech Institute.
  • Kayser, V. (2012). Mechanistic Insights into Protein Aggregation and the Development of Rational Approaches and Predictive Tools to Stabilization of Biopharmaceuticals. International Conference and Exhibition on Biowaivers and Biosimilars.

2011

  • Kayser, V., Chennamsetty, N., Voynov, V., Helk, B., Trout, B. (2011). Conformational stability and aggregation of therapeutic monoclonal antibodies studied with ANS and Thioflavin T binding. mAbs, 3(4), 408-411. [More Information]
  • Kayser, V., Chennamsetty, N., Voynov, V., Helk, B., Forrer, K., Trout, B. (2011). Evaluation of a Non-Arrhenius Model for Therapeutic Monoclonal Antibody Aggregation. Journal of Pharmaceutical Sciences, 100(7), 2526-2542. [More Information]
  • Kayser, V., Chennamsetty, N., Voynov, V., Forrer, K., Helk, B., Trout, B. (2011). Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies. Biotechnology Journal, 6(1), 38-44. [More Information]
  • Chennamsetty, N., Voynov, V., Kayser, V., Helk, B., Trout, B. (2011). Prediction of protein binding regions. Proteins: Structure, Function, and Bioinformatics, 79(3), 888-897. [More Information]
  • Kayser, V., Chennamsetty, N., Voynov, V., Helk, B., Trout, B. (2011). Tryptophan-Tryptophan Energy Transfer and Classification of Tryptophan Residues in Proteins Using a Therapeutic Monoclonal Antibody as a Model. Journal of Fluorescence, 21(1), 275-288. [More Information]

2010

  • Kayser, V. (2010). Degradation of Biological Drugs: Understanding and Modeling of Therapeutic mAb Aggregation & Improved Formulations of Vaccines. Bio-manufacturing (BioMAN).
  • Voynov, V., Chennamsetty, N., Kayser, V., Wallny, H., Helk, B., Trout, B. (2010). Design and Application of Antibody Cysteine Variants. Bioconjugate Chemistry, 21(2), 385-392. [More Information]
  • Chennamsetty, N., Helk, B., Kayser, V., Trout, B., Voynov, V. (2010). Methods for identification of sites for IgG conjugation. Patent No. WO 2010141902 A2 20101209.
  • Chennamsetty, N., Voynov, V., Kayser, V., Helk, B., Trout, B. (2010). Prediction of Aggregation Prone Regions of Therapeutic Proteins. Russian Journal of Physical Chemistry B, 114(9), 6614-6624. [More Information]
  • Kayser, V. (2010). Understanding and Modeling of Therapeutic Monoclonal Antibody Aggregation. American Chemical Society Annual Meeting.

2009

  • Chennamsetty, N., Helk, B., Voynov, V., Kayser, V., Trout, B. (2009). Aggregation-Prone Motifs in Human Immunoglobulin G. Journal of Molecular Biology, 391(2), 404-413. [More Information]
  • Kayser, V. (2009). Characterization of Rabies Virus Vaccine Inactivation. American Institute of Chemical Engineers Annual Meeting.
  • Chennamsetty, N., Voynov, V., Kayser, V., Helk, B., Trout, B. (2009). Design of therapeutic proteins with enhanced stability. Proceedings of the National Academy of Sciences of the United States of America, 106(29), 11937-11942. [More Information]
  • Voynov, V., Chennamsetty, N., Kayser, V., Helk, B., Forrer, K., Zhang, H., Fritsch, C., Heine, H., Trout, B. (2009). Dynamic Fluctuations of Protein-Carbohydrate Interactions Promote Protein Aggregation. PloS One, 4(12), 1-10. [More Information]
  • Kayser, V. (2009). Elucidating & Predicting Therapeutic Monoclonal Antibody Aggregation. Novartis Institutes for Biomedical Research.
  • Chennamsetty, N., Helk, B., Kayser, V., Trout, B., Voynov, V. (2009). Immunoglobulins with reduced aggregation. Patent No. WO 2009155513 A2 20091223.
  • Chennamsetty, N., Helk, B., Trout, B., Kayser, V., Voynov, V. (2009). Methods to identify macromolecule binding and aggregation prone regions in proteins and uses therefore. Patent No. WO 2009155518 A1 20091223.
  • Voynov, V., Chennamsetty, N., Kayser, V., Helk, B., Trout, B. (2009). Predictive tools for stabilization of therapeutic proteins. mAbs, 1(6), 580-582. [More Information]
  • Kayser, V. (2009). Stability and Aggregation of Therapeutic Monoclonal Antibodies: Determination of Aggregation Kinetic Rates with Accelerated Studies. American Institute of Chemical Engineers Annual Meeting.

2008

  • Kayser, V. (2008). Elucidating Therapeutic Monoclonal Antibody Aggregation. American Institute of Chemical Engineers AnnualMeeting.

2005

  • Bartlett, S., Beddard, G., Jackson, R., Kayser, V., Kilner, C., Leach, A., Nelson, A., Oledzki, P., Parker, P., Reid, G., et al (2005). Comparison of the ATP binding sites of protein kinases using conformationally diverse bisindolylmaleimides. Journal of the American Chemical Society, 127(33), 11699-11708. [More Information]

2004

  • Kayser, V., Turton, D., Aggeli, A., Beevers, A., Reid, G., Beddard, G. (2004). Energy migration in novel pH-Triggered self-assembled beta-sheet ribbons. Journal of the American Chemical Society, 126(1), 336-343. [More Information]

2003

  • Kayser, V. (2003). Fast Dynamics in Engineered Self-Assembling Peptide Systems. ANUMOCP 13th Annual Symposium.
  • Kayser, V. (2003). Fluorescence Properties of Engineered Novel Self-Assembling Peptide Systems. NESBiC Annual Symposium.
  • Kayser, V. (2003). Ultrafast Spectroscopy of Designed Novel Self-Assembling Peptides. 3rd Year Talk.

2002

  • Reid, G., Whittaker, D., Day, M., Turton, D., Kayser, V., Kelly, J., Beddard, G. (2002). Femtosecond electron-transfer reactions in mono- and polynucleotides and in DNA. Journal of the American Chemical Society, 124(19), 55118-5527. [More Information]

For support on your academic profile contact .